Skip to main content

Immunology

Monoclonal Gammopathies

So far, we’ve discussed the immune system’s response to outside threats (hypersensitivity) or its mistaken attacks on itself (autoimmunity). Now, we’re going to talk about what happens when the cells of the immune system themselves become cancerous. This is the world of immunoproliferative diseases

Specifically, we’re focusing on a group of disorders called monoclonal gammopathies. To understand this, let’s use an analogy. A normal, healthy immune response is polyclonal. Imagine a town with thousands of different, small, specialized workshops (B-cell clones), each producing a unique, custom product (a specific antibody) to meet a specific need. It’s a diverse, responsive, and well-regulated economy

A monoclonal gammopathy is what happens when one of those workshops goes rogue. A single clone of a B-cell or plasma cell begins to proliferate uncontrollably, becoming a massive, unregulated factory. This factory ignores all stop signals and starts churning out an enormous quantity of a single, identical, and often useless product: a monoclonal immunoglobulin. In the lab, we call this abnormal protein an M-protein, paraprotein, or M-spike. Our job, as Medical Laboratory Scientists, is to detect, identify, and quantify this M-protein, which is the “smoking gun” of these diseases

Plasma Cell Myeloma (Multiple Myeloma): The Bone Marrow Factory

This is the most common and clinically significant of the malignant monoclonal gammopathies. It is a cancer of terminally differentiated plasma cells that take over the bone marrow

Pathophysiology: What the Rogue Factory Does

The malignant plasma cells don’t just sit there. They cause widespread damage in several ways, which can be remembered by the mnemonic CRAB: * C - Calcium elevation: The cancer cells produce factors that stimulate osteoclasts to break down bone, releasing large amounts of calcium into the blood (hypercalcemia) * R - Renal failure: The massive amounts of monoclonal light chains (called Bence Jones proteins) are toxic to the kidneys and can clog the renal tubules. Hypercalcemia also contributes to kidney damage * A - Anemia: The bone marrow becomes so packed with cancerous plasma cells that there is no room left for normal hematopoietic cells to grow. This “crowding out” effect leads to anemia, leukopenia, and thrombocytopenia * B - Bone lesions: The overactive osteoclasts chew “punched-out” lytic lesions into the bone, which are visible on X-ray and can lead to fractures and severe bone pain

Laboratory Diagnosis: Finding the M-Protein

This is where the clinical immunology and chemistry labs become the central players. We use a multi-step process to hunt down the M-protein

1. Screening: Serum Protein Electrophoresis (SPEP)

  • The Principle: This is our wide-angle lens. We take the patient’s serum and separate the proteins based on their size and electrical charge in an agarose gel. Normally, the gamma globulin zone is a broad, diffuse smear, representing the thousands of different polyclonal antibodies
  • The Finding in Myeloma: In a monoclonal gammopathy, the SPEP shows a dense, narrow, well-defined band, most often in the gamma region. On a densitometer scan, this appears as a tall, sharp “spike”. This is the M-spike, representing the massive overproduction from a single clone

2. Identification: Immunofixation Electrophoresis (IFE)

  • The Principle: The SPEP tells us that there’s a monoclonal protein, but it doesn’t tell us what it is. IFE is our high-powered microscope. After electrophoresis, we apply specific antisera against different heavy chains (G, A, M) and light chains (kappa, lambda) to separate lanes
  • The Finding in Myeloma: We are looking for a sharp, discrete band in one heavy chain lane that corresponds perfectly with a sharp band in one light chain lane. This allows us to definitively identify the M-protein
    • The most common type in myeloma is IgG kappa (~55% of cases), followed by IgA. IgM myeloma is very rare
    • About 20% of cases are “light chain only,” where the cells only produce and secrete monoclonal free light chains, and no heavy chain is seen on IFE

3. Urine Testing: The Hunt for Bence Jones Proteins

  • It is absolutely critical to also analyze the patient’s urine using Urine Protein Electrophoresis (UPEP) and Urine Immunofixation (UIFE)
  • Bence Jones proteins: are monoclonal free light chains (kappa or lambda) that are small enough to be filtered by the kidneys and excreted in the urine. Their presence is a hallmark of plasma cell myeloma and contributes significantly to renal failure

4. Quantitation & Other Findings

  • We quantify the size of the M-spike on SPEP and also measure the levels of the patient’s normal immunoglobulins (IgG, IgA, IgM). A classic finding is that the M-protein is very high, while the other, uninvolved immunoglobulins are suppressed (immunosuppression), leaving the patient vulnerable to infections
  • Hematology: The peripheral smear may show rouleaux formation, where red blood cells stack up like coins due to the high protein content of the plasma
  • Chemistry: Will show hypercalcemia and elevated creatinine (indicating renal dysfunction)

Waldenström Macroglobulinemia: The IgM Problem

Waldenström’s is another monoclonal gammopathy, but it’s important to know how it’s different from myeloma

  • The Cell: It is a cancer of a lymphoplasmacytic cell, a cell that is more mature than a B-lymphocyte but not quite a fully differentiated plasma cell. It is considered a type of lymphoma
  • The M-Protein: The defining feature of Waldenström’s is that the monoclonal protein is always IgM. The “M” in IgM is for “Macro,” meaning it’s a huge pentameric molecule
  • The Primary Problem: Hyperviscosity Syndrome
    • Myeloma’s main problems are in the bones and kidneys. Waldenström’s main problem is in the blood itself
    • The massive amount of large IgM protein literally turns the blood thick and syrupy, like molasses. This hyperviscosity makes it difficult for blood to flow through small vessels, leading to a classic triad of symptoms: blurry vision, neurological issues (like headaches or dizziness), and bleeding
  • Lab Diagnosis: The lab workup is identical to that for myeloma (SPEP and IFE). The key diagnostic finding will be a monoclonal IgM protein (either IgM kappa or IgM lambda). Bone lesions are notably absent in Waldenström’s

Monoclonal Gammopathy of Undetermined Significance (MGUS)

It is crucial to know that not every M-protein means cancer. MGUS is a common, pre-malignant condition, especially in the elderly, where a small M-protein is present but the patient has no CRAB symptoms or other signs of malignancy. These patients are not treated but are monitored closely, as about 1% per year will progress to full-blown myeloma or another related disorder